Children's Medical Center Corporation

Hwei-Ling Cheng

Frederick W Alt

Ming Tian

Raul Mostoslavsky

David B Lombard

Katrin F Chua

Frederick Alt

Described herein are novel anti-PD1 antibody reagents (e.g., antibodies, antigen-binding fragments thereof, and/or chimeric antigen receptors). Also described herein antibody-drug conjugates or kits comprising the disclosed antibody reagents, as well as methods of treating cancer by administering the disclosed antibody reagents.

Methods and compositions relating to anti-PD1 antibody reagents

Described herein are compositions (e.g. cells and transgenic animals) and methods relating to engineered Ig loci that permit expression of particular antibodies or antibody segments while still permitting recombination and/or maturation process for antibody optimization.

High-throughput mouse model for optimizing antibody affinities

The present invention is directed to methods for enhancing the replicative capacity of cells, by culturing the cells in the presence of an active agent or compound which inhibits SIRT1. One method provides expanding stem cells by culturing the cells in the presence of a SIRT1 inhibitor. The resulting cultured cells can be used for a variety of applications including cell-based therapies such as bone marrow transplants, gene therapies, tissue engineering, and in vitro organogenesis.

Growing community of inventors

Northborough, MA, United States of America

Hwei-Ling Cheng